Late-onset Hypogonadism and Testosterone Therapy – A Summary of Guidelines from the American Urological Association and the European Association of Urology

Mikkel Fode, Andrea Salonia, Suks Minhas, Arthur L. Burnett, Alan W. Shindel

Research output: Contribution to journalArticle

Abstract

Men with low serum testosterone and symptoms of androgen deficiency may be diagnosed with testosterone deficiency. This condition is associated with metabolic syndrome and cardiovascular disease. The benefits (eg, improvement in sexual function) and risks (eg, prostate cancer and cardiovascular disease) of testosterone therapy are controversial. The American Urological Association and European Association of Urology guidelines on testosterone therapy differ on several points of management, likely reflecting the ambiguities surrounding testosterone therapy in practice. This paper summarizes both guidelines with a focus on the differences between the two sets of guidelines. Patient summary: The benefits and risks of testosterone therapy are controversial, as reflected in the European Association of Urology and American Urological Association guidelines that differ on several points of management. The benefits and risks of testosterone therapy are controversial, and ambiguities surround testosterone therapy in practice. This is reflected in the European Association of Urology and American Urological Association guidelines, as these differ on several points of management.

Original languageEnglish (US)
JournalEuropean Urology Focus
DOIs
StatePublished - Jan 1 2019

Fingerprint

Hypogonadism
Testosterone
Guidelines
Therapeutics
Cardiovascular Diseases
Metabolic Diseases
Androgens
Prostatic Neoplasms
Serum

Keywords

  • Androgens
  • Erectile dysfunction
  • Hypogonadism
  • Libido
  • Lifestyle
  • Major cardiac adverse event
  • Prostate cancer
  • Sexual desire
  • Testosterone
  • Testosterone deficiency
  • Testosterone replacement therapy

ASJC Scopus subject areas

  • Urology

Cite this

Late-onset Hypogonadism and Testosterone Therapy – A Summary of Guidelines from the American Urological Association and the European Association of Urology. / Fode, Mikkel; Salonia, Andrea; Minhas, Suks; Burnett, Arthur L.; Shindel, Alan W.

In: European Urology Focus, 01.01.2019.

Research output: Contribution to journalArticle

@article{4be5fdb80cab47c6a43898346db80ed2,
title = "Late-onset Hypogonadism and Testosterone Therapy – A Summary of Guidelines from the American Urological Association and the European Association of Urology",
abstract = "Men with low serum testosterone and symptoms of androgen deficiency may be diagnosed with testosterone deficiency. This condition is associated with metabolic syndrome and cardiovascular disease. The benefits (eg, improvement in sexual function) and risks (eg, prostate cancer and cardiovascular disease) of testosterone therapy are controversial. The American Urological Association and European Association of Urology guidelines on testosterone therapy differ on several points of management, likely reflecting the ambiguities surrounding testosterone therapy in practice. This paper summarizes both guidelines with a focus on the differences between the two sets of guidelines. Patient summary: The benefits and risks of testosterone therapy are controversial, as reflected in the European Association of Urology and American Urological Association guidelines that differ on several points of management. The benefits and risks of testosterone therapy are controversial, and ambiguities surround testosterone therapy in practice. This is reflected in the European Association of Urology and American Urological Association guidelines, as these differ on several points of management.",
keywords = "Androgens, Erectile dysfunction, Hypogonadism, Libido, Lifestyle, Major cardiac adverse event, Prostate cancer, Sexual desire, Testosterone, Testosterone deficiency, Testosterone replacement therapy",
author = "Mikkel Fode and Andrea Salonia and Suks Minhas and Burnett, {Arthur L.} and Shindel, {Alan W.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.euf.2019.02.021",
language = "English (US)",
journal = "European Urology Focus",
issn = "2405-4569",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Late-onset Hypogonadism and Testosterone Therapy – A Summary of Guidelines from the American Urological Association and the European Association of Urology

AU - Fode, Mikkel

AU - Salonia, Andrea

AU - Minhas, Suks

AU - Burnett, Arthur L.

AU - Shindel, Alan W.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Men with low serum testosterone and symptoms of androgen deficiency may be diagnosed with testosterone deficiency. This condition is associated with metabolic syndrome and cardiovascular disease. The benefits (eg, improvement in sexual function) and risks (eg, prostate cancer and cardiovascular disease) of testosterone therapy are controversial. The American Urological Association and European Association of Urology guidelines on testosterone therapy differ on several points of management, likely reflecting the ambiguities surrounding testosterone therapy in practice. This paper summarizes both guidelines with a focus on the differences between the two sets of guidelines. Patient summary: The benefits and risks of testosterone therapy are controversial, as reflected in the European Association of Urology and American Urological Association guidelines that differ on several points of management. The benefits and risks of testosterone therapy are controversial, and ambiguities surround testosterone therapy in practice. This is reflected in the European Association of Urology and American Urological Association guidelines, as these differ on several points of management.

AB - Men with low serum testosterone and symptoms of androgen deficiency may be diagnosed with testosterone deficiency. This condition is associated with metabolic syndrome and cardiovascular disease. The benefits (eg, improvement in sexual function) and risks (eg, prostate cancer and cardiovascular disease) of testosterone therapy are controversial. The American Urological Association and European Association of Urology guidelines on testosterone therapy differ on several points of management, likely reflecting the ambiguities surrounding testosterone therapy in practice. This paper summarizes both guidelines with a focus on the differences between the two sets of guidelines. Patient summary: The benefits and risks of testosterone therapy are controversial, as reflected in the European Association of Urology and American Urological Association guidelines that differ on several points of management. The benefits and risks of testosterone therapy are controversial, and ambiguities surround testosterone therapy in practice. This is reflected in the European Association of Urology and American Urological Association guidelines, as these differ on several points of management.

KW - Androgens

KW - Erectile dysfunction

KW - Hypogonadism

KW - Libido

KW - Lifestyle

KW - Major cardiac adverse event

KW - Prostate cancer

KW - Sexual desire

KW - Testosterone

KW - Testosterone deficiency

KW - Testosterone replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=85062463661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062463661&partnerID=8YFLogxK

U2 - 10.1016/j.euf.2019.02.021

DO - 10.1016/j.euf.2019.02.021

M3 - Article

C2 - 30858073

AN - SCOPUS:85062463661

JO - European Urology Focus

JF - European Urology Focus

SN - 2405-4569

ER -